We’re addressing a huge unmet medical need
Bengt von Mentzer, founder, and chief scientific advisor

About us » This is PharmNovo

Lacking of sufficient treatments

PharmNovo AB is a clinical-phase pharmaceutical company focused on developing safe and effective drugs for neuropathic pain.

Neuropathic pain affects up to ten percent of the population in Europe and the United States, and there is a lack of sufficient treatment.  Existing chronic pain drugs are only partly effective and only for some patients, and they are associated with significant side effects.

PharmNovo’s mission is to develop safe and effective treatments for neuropathic pain to accomplish our vision to change the lives of people suffering from this condition.

The company's drug candidate, PN6047, about to enter phase II proof-of-concept studies, has effectively reduced neuropathic pain in preclinical studies. The primary indication is neuropathic pain with allodynia, which is a condition where, for example, light touch triggers severe pain. PharmNovo also sees clinical potential for the drug in other areas, such as migraine, anxiety/depression, and chronic cough.

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Visionaries in pain relief: PharmNovo presents Bengt von Mentzer, founder and Chief scientific advisor.

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more